Three different KRAS statuses in three synchronous colorectal cancers.

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Targeted therapies, including monoclonal antibodies against epidermal growth factor receptors (EGFR), have significantly advanced metastatic colorectal cancer (CRC) treatment.
• KRAS mutation status is a critical biomarker, predicting resistance to anti-EGFR agents and identifying patients likely to benefit from these therapies.

Observation:

• This report details an unprecedented case of metastatic CRC presenting with three synchronous primary tumors.
• Remarkably, each of these primary tumors exhibited a distinct KRAS mutation status (mutated vs. wild-type).

Findings:

• The presence of multiple primary tumors with varying KRAS statuses in a single patient is a rare clinical occurrence.
• This heterogeneity challenges standard diagnostic and therapeutic paradigms for metastatic CRC.

Implications:

• This case underscores the potential clinical impact of intratumoral heterogeneity in KRAS status within metastatic CRC.
• It emphasizes the critical need for comprehensive molecular profiling, potentially involving multiple tumor sampling, to guide personalized anti-EGFR therapy selection and optimize patient outcomes.